Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia

Blood

Volumn 119, Issue 12, 2012, Pages 2873-2882

  Zhao, Li Juan ^a   Wang, Yue Ying ^a   Li, Guo ^a   Ma, Li Yuan ^a   Xiong, Shu Min ^a   Weng, Xiang Qin ^a   Zhang, Wei Na ^a   Wu, Bo ^a   Chen, Zhu ^a   Chen, Sai Juan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; GENOMIC DNA; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR RUNX1; YELLOW FLUORESCENT PROTEIN;

ADULT; ANIMAL CELL; ARTICLE; BLOOD CELL; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CHINESE; CHROMOSOME 21Q; CHROMOSOME 9; CHROMOSOME LOSS; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DIMERIZATION; DISEASE COURSE; DNA BINDING; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MOUSE; MURINE LEUKEMIA; MUTATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; TRISOMY;

EID: 84863356975     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-370981     Document Type: Article

References (46)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-3356.
2. Miyazaki K, Yamasaki N, Oda H, et al. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia. Blood. 2009; 113(19):4702-4710.
3. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183. (Pubitemid 40314949)
4. Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008;2008:436-442.
5. Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program. 2007; 2007:384-391.
6. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010-4022. (Pubitemid 38685338)
7. Cuenco GM, Ren R. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene. 2001;20(57):8236- 8248.
8. Mayotte N, Roy DC, Yao J, Kroon E, Sauvageau G. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood. 2002; 100(12):4177-4184. (Pubitemid 35396886)
9. Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A. 1996;93(22):12359-12363. (Pubitemid 26367148)
10. Nucifora G, Rowley JD. Aml1 and the 8-21 and 3-21 Translocations in Acute and Chronic Myeloid- Leukemia. Blood. 1995;86(1):1-14.
11. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93(6):1817- 1824.
12. Hart SM, Foroni L. Core binding factor genes and human leukemia. Haematologica. 2002;87(12): 1307-1323. (Pubitemid 36005305)
13. Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352-5361.
14. Tsuzuki S, Seto M, Greaves M, Enver T. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci U S A. 2004; 101(22):8443-8448. (Pubitemid 38736594)
15. Roche-Lestienne C, Deluche L, Corm S, et al. RUNX1 DNA-binding mutations and RUNX1- PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008;111(7):3735- 3741.
16. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3): 557-560.
17. Zhang SJ, Ma LY, Huang QH, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2008;105(6):2076-2081.
18. Wang YY, Zhao LJ, Wu CF, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2011;108(6):2450-2455.
19. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101(2):673-680. (Pubitemid 36077592)
20. Chakraborty S, Sinha KK, Senyuk V, Nucifora G. SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo. Oncogene. 2003;22(34):5229-5237. (Pubitemid 37056085)
21. Vradii D, Zaidi SK, Lian JB, van Wijnen AJ, Stein JL, Stein GS. Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype. Proc Natl Acad Sci U S A. 2005;102(20): 7174-7179. (Pubitemid 40696353)
22. Menke A, McInnes L, Hastie ND, Schedl A. The Wilms' tumor suppressor WT1: approaches to gene function. Kidney Int. 1998;53(6):1512-1518. (Pubitemid 28243735)
23. Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/ Runx-1 Runt domain and its allosteric control by CBFbeta. Cell. 2001;104(5):755-767. (Pubitemid 32241025)
24. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106(2):494-504. (Pubitemid 40981243)
25. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330. (Pubitemid 26042836)
26. Imai Y, Kurokawa M, Izutsu K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood. 2000;96(9):3154-3160.
27. Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol. 1994;14(12):8085-8095. (Pubitemid 24373557)
28. Austin GE, Zhao WG, Regmi A, Lu JP, Braun J. Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. Leukemia Research. 1998;22(11): 1037-1048. (Pubitemid 28454504)
29. Li XG, Vradii D, Gutierrez S, et al. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU. 1. J Cell Biochem. 2005;96(4): 795-809. (Pubitemid 41567550)
30. Halle JP, HausSeuffert P, Woltering C, Stelzer G, Meisterernst M. A conserved tissue-specific structure at a human T-cell receptor beta-chain core promoter. Mol Cell Biol. 1997;17(8):4220-4229.
31. Bakshi R, Hassan MQ, Pratap J, et al. The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J Cell Physiol. 2010;225(2):569-576.
32. Uchida H, Zhang J, Nimer SD. AML1A and AML1B can transactivate the human IL-3 promoter. J Immunol. 1997;158(5):2251-2258. (Pubitemid 127470009)
33. Li D, Sinha KK, Hay MA, Rinaldi CR, Saunthararajah Y, Nucifora G. RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function. J Biol Chem. 2007;282(18):13542- 13551.
34. Chen G, Nguyen PH, Courey AJ. A role for Groucho tetramerization in transcriptional repression. Mol Cell Biol. 1998;18(12):7259-7268. (Pubitemid 28533045)
35. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995; 267(5203):1498-1502.
36. John S, Vinkemeier U, Soldaini E, Darnell JE, Jr., Leonard WJ. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol. 1999;19(3):1910-1918. (Pubitemid 29098249)
37. Jousset C, Carron C, Boureux A, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 1997;16(1):69-82. (Pubitemid 27032851)
38. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Molecular Cell. 2000;5(5):811-820.
39. Kwok C, Zeisig BB, Qiu JH, Dong SO, So CWE. Transforming activity of AML1-ETO is independent of CBF beta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A. 2009;106(8):2853- 2858.
40. Senyuk V, Li D, Zakharov A, Mikhail FM, Nucifora G. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro. Cancer Res. 2005;65(17):7603-7611. (Pubitemid 41297232)
41. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99(4):1364-1372. (Pubitemid 34547093)
42. Lu J, Maruyama M, Satake M, et al. Subcellular localization of the alpha-subunits and betasubunits of the acute myeloid leukemia-linked transcription factor Pebp2/Cbf. Mol Cell Biol. 1995;15(3):1651-1661.
43. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284-4296. (Pubitemid 38765137)
44. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009;114(25):5201- 5205.
45. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008;111(8):4297- 4308.
46. Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto M, Enver T. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med. 2007;4(5):e172.